Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These two Patents for $ONCS were part of the deal?
$ELTP MA(50) = $0.089. $ELTP new HOD is $0.09
$ELTP new HOD $0.09
Yup CDN$3.84 = US$3.00
mgplayer247 Very bullish. IYO What is the strength for Glance?
$ELTP new HOD $0.0899
C$3.00 per Unit = US$2.34
Yes IMO there is a Japanese connection for $ONCS
Both of these IP are Japanese IP it seems. Looking for more details
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform
PR NEWSWIRE 8:00 AM ET 11/28/2017
Symbol Last Price Change
ONCS 1.99down 0 (0%)
QUOTES AS OF 04:00:00 PM ET 11/27/2017
SAN DIEGO , Nov. 28, 2017 /PRNewswire/ -- OncoSec Medical Incorporated(ONCS) ("OncoSec" or the "Company") , a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio.
The first patent, JP06174632, encompasses a device for post-resection electroporation ("EP") delivery of an agent (including nucleic acids) to prevent recurrence of resected tumors and expires in 2030. The patent family was added to the Company's portfolio as part of a 2011 asset purchase agreement.
The second patent, US 9,610,634, adds to the ImmunoPulse® IL-12 portfolio, and includes coverage for reducing tumor angiogenesis while increasing T cell proliferation by the EP delivery of plasmid encoded IL-12. The second patent expires in 2025.
"OncoSec is continuing to build a broad portfolio of patent assets encompassing compositions of matter and methods of use across diverse oncology applications with compelling unmet needs," said Daniel J. O'Connor, Chief Executive Officer of OncoSec. "We are pleased with the progress of the ongoing PISCES/KEYNOTE-695 clinical trial which benefits, in part, from the second issued patent."
About Metastatic Melanoma1
Melanoma is a type of skin cancer that begins in skin cells called melanocytes. As the cancer progresses, melanoma becomes more difficult to treat once it spreads beyond the skin, such as the lymphatic system (metastatic disease). Given its occurrence young individuals, the potential years of life lost to melanoma can be higher when compared with other cancers. Although melanoma is a rare form of skin cancer, it accounts for over 75% of skin cancer deaths. The American Cancer Society estimates that approximately 87,000 new melanoma cases and 10,000 deaths from the disease will occur in the United States in 2017. Additionally, the World Health Organization estimates that approximately 132,000 new cases of melanoma are diagnosed around the world every year.
1 American Cancer Society (https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html); World Health Organization (http://www.who.int/uv/faq/skincancer/en/index1.html)
About PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study)/KEYNOTE-695
PISCES/KEYNOTE-695 is a global, multicenter phase 2b, open-label trial of intratumoral plasma encoded IL-12 (tavokinogene telseplasmid or "tavo") delivered by electroporation in combination with intravenous pembrolizumab in patients with stage III/IV melanoma who have progressed or are progressing on either pembrolizumab or nivolumab treatment. The Simon 2-stage study of intratumoral tavo plus electroporation in combination with pembrolizumab will enroll approximately 48 patients with histological diagnosis of melanoma with progressive locally advanced or metastatic disease defined as Stage III or Stage IV. The primary endpoint will be the Best Overall Response Rate (BORR).
To learn more about the trial, visit www.oncosec.com. Additional details can also be found at www.clinicaltrials.gov via NCT03132675
About OncoSec Medical Incorporated(ONCS)
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical trials, ImmunoPulse® IL-12 has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse IL-12, is currently in clinical development for metastatic melanoma and triple-negative breast cancer. The program's current focus is on the significant unmet medical need in patients with melanoma who are refractory or have relapsed on anti-PD-1 therapies. In addition to tavo, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse platform. For more information, please visit www.oncosec.com.
Yes most definitely.
newguy11 Interactive brokers have 1 mil shs ELTP available to Short.
https://www.interactivebrokers.com/en/index.php?f=4587&cntry=usa&tag=United%20States&ib_entity=am&ln=&asset=&b=ELP&e=ENS&conf=am
$ELTP new HOD $0.0852
$ELTP 195K Bid @ $0.083
$ELTP new HOD $0.084 and looking to go higher.
CoastalTrader83 Most welcome. Keep posting and spread the word about $VCEL!
11/21/2017 DUTASTERIDE
ANDA #209909 ORIG-1 DUTASTERIDE HUMANWELL PURACAP Approval
Yes HUMANWELL PURACAP is one and the same company.
hschlauch which BPs do you envision will be Partnering with $ONCS ?
That is correct. We are waiting for the FDA record on Elite to be updated with the Closeout Date
It is the status link that we are following. It is there now
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2016/default.htm?Page=5
My conclusion also.
Elite is not there now 7:05 PM
Others like "Jeffreys Drug Store" that received a warning letter at the same time 8/25/2016 as Elite seems to be on-line at all times, at least every time I checked.
Checked Elite again now at 4:43 PM and it is nether on Page 5 or 6
https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2016/default.htm?Page=5
Strange again why Elite has disappeared again and on a Sat. It was there earlier today and has since been taken offline.
With the $ELTP PPS closing at $0.083 on Fri 1 PM NY EOD, a move upwards seems to have been started. No shares below $0.08, it seems, were available for purchase by Retail. MMs doing their thing of whatever as the PPS moved up to $0.083.
Thin trading Fri as Mkt closed at 1 PM NY.
EOY for $VCEL finances should be good with MACI procedures increasing. As well looking for ICT news.
As for PPS is anybody's guess.
In one year's time $ONCS shareholders will vote on whether to award Dan O'Connor the 2 mil shares. Dan has to earn it.
Yes that is the situation.
It is back again now. However the 8/25/2016 FDA notification will remain on this site with a "Close Out Date" showing the date when it is all settled after $ELTP receives the FDA official ADE SOP Site Registered Clearance letter
Yes a close at 2.20 or higher is a "psychological" level.
Institutionals IMO with +$3 mil purchases today.
Bid raised now to $2.21. Breaking thru the resistance.
Yup more churning at $2.19/$2.20 before we see $2.21/$2.25
AS well you also. Have a great thanksgiving.
Yes it is back again
Yes they are very nervous and trying their hardest to hold $ONCS below $2.20.
That is not a problem as Street readers always read AF details on the biotechs.
Not a genius. AF simply highlighting the important Clinical Trial details for his own and the Street's large biotech readership.
Yes IMO also. AF has become a respected independent biotech analyst!